Illustrating riskvsbenefit with the tiotropium Respimat inhaler

    loading  Checking for direct PDF access through Ovid

Abstract

Patient decision aids present evidence-based estimates of the risks and benefits of a particular treatment. Here, Dr Chris Cates illustrates the benefit of tiotropium in reducing exacerbations in COPD and the increased risk of mortality associated with administration via the Respimat inhaler.

Related Topics

    loading  Loading Related Articles